Epaxal®: A virosomal vaccine to prevent hepatitis A infection

Expert Review of Vaccines

Volumn 7, Issue 8, 2008, Pages 1141-1150

  Bovier, Patrick A ^a  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

Hepatitis A; Hepatitis A vaccine; Virosome

Indexed keywords

ALUMINUM HYDROXIDE; EPAXAL JUNIOR; FORMALDEHYDE; HAVRIX 720; HEPATITIS A VACCINE; UNCLASSIFIED DRUG; VIROSOME; VIROSOME VACCINE;

ANOREXIA; DRUG FORMULATION; DRUG TOLERABILITY; FEVER; HEADACHE; HEPATITIS A; HEPATITIS A VIRUS; HUMAN; IMMUNOGENICITY; INJECTION SITE ERYTHEMA; INJECTION SITE INDURATION; INJECTION SITE PAIN; INJECTION SITE SWELLING; MALAISE; NAUSEA; PRIORITY JOURNAL; REVIEW; SINGLE DRUG DOSE; VIRUS INACTIVATION; VIRUS STRAIN; ADOLESCENT; ADULT; CHILD; IMMUNOLOGY; INFANT; PRESCHOOL CHILD;

ADOLESCENT; ADULT; CHILD; CHILD, PRESCHOOL; HEPATITIS A; HEPATITIS A VACCINES; HEPATITIS A VIRUS; HUMANS; INFANT; VACCINES, VIROSOME;

EID: 53849128926     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/14760584.7.8.1141     Document Type: Review

References (58)

1. Hepatitis A: a vaccine at last. Lancet 339(8803), 1198-1199 (1992).
2. Steffen R, Kane MA, Shapiro CN, Billo N, Schoellhorn KJ, van Damme P. Epidemiology and prevention of hepatitis A in travelers. JAMA 272(11), 885-889 (1994).
3. Bell BP, Anderson DA, Feinstone SM. Hepatitis A virus. In: Principles and Practices of Infectious Diseases. Mandell GL, Bennett JE, Dolin R (Eds). Elsevier Churchill Livingstone, PA, USA 2162-2185 (2005).
4. Crowcroft NS, Walsh B, Davison KL, Gungabissoon U. Guidelines for the control of hepatitis A virus infection. Commun. Dis. Public Health 4(3), 213-227 (2001).
5. Willner IR, Uhl MD, Howard SC, Williams EQ, Riely CA, Waters B. Serious hepatitis A: an analysis of patients hospitalized during an urban epidemic in the United States. Ann Intern Med. 128(2), 111-114 (1998).
6. Vogt TM, Wise ME, Bell BP, Finelli L. Declining hepatitis A mortality in the United States during the era of hepatitis A vaccination. J. Infect. Dis. 197(9), 1282-1288 (2008).
7. Forbes A, Williams R. Changing epidemiology and clinical aspects of hepatitis A. Br. Med. Bull. 46(2), 303-318 (1990).
8. Melnick JL. History and epidemiology of hepatitis A virus. J Infect Dis. 171(Suppl. 1), S2-S8 (1995).
9. Armstrong GL, Bell BP. Hepatitis A virus infections in the United States: modelbased estimates and implications for childhood immunization. Pediatrics 109(5), 839-845 (2002).
10. Dagan R, Leventhal A, Anis E, Slater P, Ashur Y, Shouval D. Incidence of hepatitis A in Israel following universal immunization of toddlers. JAMA 294(2), 202-210 (2005).
11. Wasley A, Samandari T, Bell BP. Incidence of hepatitis A in the United States in the era of vaccination. JAMA 294(2), 194-201 (2005).
12. Dominguez A, Oviedo M, Carmona G et al. Impact and effectiveness of a mass hepatitis A vaccination programme of preadolescents seven years after introduction. Vaccine 26(14), 1737-1741 (2008).
13. Hanna JN, Hills SL, Humphreys JL. Impact of hepatitis A vaccination of Indigenous children on notifications of hepatitis A in north Queensland. Med. J. Australia 181(9), 482-485 (2004).
14. Lopalco PL, Prato R, Chironna M, Germinario C, Quarto M. Control of hepatitis A by universal vaccination of adolescents, Puglia, Italy. Emerg. Infect. Dis. 14(3), 526-528 (2008).
15. Averhoff F, Shapiro CN, Bell BP et al. Control of hepatitis A through routine vaccination of children. JAMA 286(23), 2968-2973 (2001).
16. Germinario C, Lopalco PL, Chirona M, Da Villa G. From hepatitis B to hepatitis A and B prevention: the Puglia (Italy) experience. Vaccine 18(Suppl. 1), S83-S85 (2000).
17. McMahon BJ, Beller M, Williams J, Schloss M, Tanttila H, Bulkow L. A program to control an outbreak of hepatitis A in Alaska by using an inactivated hepatitis A vaccine. Arch. Pediatr. Adolesc. Med. 150(7), 733-739 (1996).
18. Fiore AE, Wasley A, Bell BP. Prevention of hepatitis A through active or passive immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm. Rep. 55(RR-7), 1-23 (2006).
19. Koff RS. Hepatitis A. Lancet 351(9116), 1643-1649 (1998).
20. Wiedermann G, Ambrosch F, Kollaritsch H et al. Safety and immunogenicity of an inactivated hepatitis A candidate vaccine in healthy adult volunteers. Vaccine 8(6), 581-584 (1990).
21. Wang XY, Xu Z, Yao X et al. Immune responses of anti-HAV in children vaccinated with live attenuated and inactivated hepatitis A vaccines. Vaccine 22(15-16), 1941-1945 (2004).
22. Gluck R. Adjuvant activity of immunopotentiating reconstituted influenza virosomes (IRIVs). Vaccine 17(13-14), 1782-1787 (1999).
23. Gluck R, Metcalfe IC. New technology platforms in the development of vaccines for the future. Vaccine. 20(Suppl. 5), B10-B16 (2002).
24. Gluck R, Walti E. Biophysical validation of Epaxal Berna, a hepatitis A vaccine adjuvanted with immunopotentiating reconstituted influenza virosomes (IRIV). Dev. Biol. (Basel) 103, 189-197 (2000).
25. Gluck R, Moser C, Metcalfe IC. Influenza virosomes as an efficient system for adjuvanted vaccine delivery. Expert Opin. Biol. Ther. 4(7), 1139-1145 (2004).
26. Moser C, Metcalfe IC, Viret JF. Virosomal adjuvanted antigen delivery systems. Expert Rev. Vaccines 2(2), 189-196 (2003).
27. Bungener L, Serre K, Bijl L et al. Virosome-mediated delivery of protein antigens to dendritic cells. Vaccine 20(17-18), 2287-2295 (2002).
28. Bungener L, Huckriede A, de Mare A, de Vries-Idema J, Wilschut J, Daemen T. Virosome-mediated delivery of protein antigens in vivo: efficient induction of class I MHC-restricted cytotoxic T lymphocyte activity. Vaccine 23(10), 1232-1241 (2005).
29. D'Acremont V, Herzog C, Genton B. Immunogenicity and safety of a virosomal hepatitis A vaccine (Epaxal) in the elderly. J. Travel Med. 13(2), 78-83 (2006).
30. Genton B, D'Acremont V, Furrer HJ, Hatz C, Louis L. Hepatitis A vaccines and the elderly. Travel Med. Infect. Dis. 4(6), 303-312 (2006).
31. Usonis V, Bakasenas V, Valentelis R, Katiliene G, Vidzeniene D, Herzog C. Antibody titres after primary and booster vaccination of infants and young children with a virosomal hepatitis A vaccine (Epaxal). Vaccine 21(31), 4588-4592 (2003).
32. Dagan R, Amir J, Mijalovsky A et al. Immunization against hepatitis A in the first year of life: priming despite the presence of maternal antibody. Pediatr. Infect. Dis. J. 19(11), 1045-1052 (2000).
33. Bovier PA, Althaus B, Glueck R, Chippaux A, Loutan L. Tolerance and immunogenicity of the simultaneous administration of virosome hepatitis A and yellow fever vaccines. J. Travel Med. 6(4), 228-233 (1999).
34. Ambrosch F, Finkel B, Herzog C, Koren A, Kollaritsch H. Rapid antibody response after vaccination with a virosomal hepatitis a vaccine. Infection 32(3), 149-152 (2004).
35. Poovorawan Y, Tieamboonlers A, Chumdermpadetsuk S, Gluck R, Cryz SJ Jr. Control of a hepatitis A outbreak by active immunization of high-risk susceptible subjects. J. Infect. Dis. 169(1), 228-229 (1994).
36. Mayorga Perez O, Herzog C, Zellmeyer M, Loaisiga A, Frosner G, Egger M. Efficacy of virosome hepatitis A vaccine in young children in Nicaragua: randomized placebo-controlled trial. J. Infect. Dis. 188(5), 671-677 (2003). •• Efficacy study with Epaxal® 0.5 ml in children.
37. Innis BL, Snitbhan R, Kunasol P et al. Protection against hepatitis A by an inactivated vaccine. JAMA 271(17), 1328-1334 (1994).
38. Werzberger A, Mensch B, Kuter B et al. A controlled trial of a formalin-inactivated hepatitis A vaccine in healthy children. N. Engl. J. Med. 327(7), 453-457 (1992).
39. Dagan R, Amir J, Livni G et al. Concomitant administration of a virosome-adjuvanted hepatitis a vaccine with routine childhood vaccines at age twelve to fifteen months: a randomized controlled trial. Pediatr. Infect. Dis. J. 26(9), 787-793 (2007).
40. Pancharoen C, Mekmullica J, Thisyakorn U, Kasempimolporn S, Wilde H, Herzog C. Reduced-dose intradermal vaccination against hepatitis A with an aluminum-free vaccine is immunogenic and can lower costs. Clin. Infect. Dis. 41(10), 1537-1540 (2005).
41. Van Der Wielen M, Vertruyen A, Froesner G et al. Immunogenicity and safety of a pediatric dose of a virosome-adjuvanted hepatitis A vaccine: a controlled trial in children aged 1-16 years. Pediatr. Infect. Dis. J. 26(8), 705-710 (2007). •• Recent study comparing Epaxal 0.25 ml and Havrix 720® in children of different age groups.
42. Holzer BR, Hatz C, Schmidt-Sissolak D, Gluck R, Althaus B, Egger M. Immunogenicity and adverse effects of inactivated virosome versus alum-adsorbed hepatitis A vaccine: a randomized controlled trial. Vaccine 14(10), 982-986 (1996).
43. Bovier PA, Farinelli T, Loutan L. Interchangeability and tolerability of a virosomal and an aluminum-adsorbed hepatitis A vaccine. Vaccine 23(19), 2424-2429 (2005). •• Comparison between Epaxal 0.5 ml and Havrix 1440 in adults and their interchangeability.
44. Clarke PD, Adams P, Ibanez R, Herzog C. Rate, intensity, and duration of local reactions to a virosome-adjuvanted vs. an aluminium-adsorbed hepatitis A vaccine in UK travellers. Travel Med. Infect. Dis. 4(6), 313-318 (2006). • Describes the reactogenicity of Epaxal 0.5 ml and Havrix 1440®.
45. Beck BR, Hatz CF, Loutan L, Steffen R. Immunogenicity of booster vaccination with a virosomal hepatitis A vaccine after primary immunization with an aluminum-adsorbed hepatitis A vaccine. J. Travel Med. 11(4), 201-206 (2004). • Study about the interchangeability of Havrix 1440 with Epaxal 0.5 ml as second dose.
46. Beck BR, Hatz C, Bronnimann R, Herzog C. Successful booster antibody response up to 54 months after single primary vaccination with virosome-formulated, aluminum-free hepatitis A vaccine. Clin. Infect. Dis. 37(9), e126-128 (2003). • Study about the duration of the interval between first and second dose of Epaxal 0.5 ml.
47. van der Ploeg R, Beck BR, Froesner G, Hunt M, Herzog C, Hatz C. Successful booster response 8 to 11 years after a single primary vaccination with a virosome-formulated hepatitis A vaccine (Epaxal). Presented at: Proceedings of the 10th CISTM. Vancouver, Canada (2007).
48. Bovier PA, Bock J, Loutan L, Farinelli T, Glueck R, Herzog C. Long-term immunogenicity of an inactivated virosome hepatitis A vaccine. J. Med. Virol. 68(4), 489-493 (2002). • Follow-up study of volunteers immunized with two doses of Epaxal 0.5 ml.
49. Van Damme P, Banatvala J, Fay O et al. Hepatitis A booster vaccination: is there a need? Lancet 362(9389), 1065-1071 (2003). •• Consensus paper about the use of the different licensed hepatitis A vaccines.
50. Mengiardi B, Berger R, Just M, Gluck R. Virosomes as carriers for combined vaccines. Vaccine 13(14), 1306-1315 (1995).
51. Pregliasco F, Mensi C, Serpilli W, Speccher L, Masella P, Belloni A. Immunogenicity and safety of three commercial influenza vaccines in institutionalized elderly. Aging (Milano) 13(1), 38-43 (2001).
52. Zuccotti G, Amendola A, Vigano A et al. Long-term immunogenicity of a virosomal subunit inactivated influenza vaccine in children with asthma. Vaccine 25(37-38), 6692-6698 (2007).
53. Ellis A, Ruttimann RW, Jacobs RJ, Meyerhoff AS, Innis BL. Cost-effectiveness of childhood hepatitis A vaccination in Argentina: a second dose is warranted. Rev. Panam. Salud Publica 21(6), 345-356 (2007).
54. Poovorawan Y, Theamboonlers A, Chumdermpadetsuk S, Gluck R, Cryz SJ Jr. Safety, immunogenicity, and kinetics of the immune response to a single dose of virosome-formulated hepatitis A vaccine in Thais. Vaccine 13(10), 891-893 (1995).
55. Ambrosch F, Wiedermann G, Jonas S et al. Immunogenicity and protectivity of a new liposomal hepatitis A vaccine. Vaccine 15(11), 1209-1213 (1997).
56. Riedemann S, Reinhardt G, Ibarra H, Frosner GG. Immunogenicity and safety of a virosomal hepatitis A vaccine (Epaxal) in healthy toddlers and children in Chile. Acta Paediatr. 93(3), 412-414 (2004).
57. Loutan L, Bovier P, Althaus B, Gluck R. Inactivated virosome hepatitis A vaccine. Lancet 343(8893), 322-324 (1994).
58. Just M, Berger R, Dreschsler H, Brantschen S, Gluck R. A single vaccination with an inactivated hepatitis A liposome vaccine induces protective antibodies after only two weeks. Vaccine 10(11), 737-739 (1992).